Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 3
2000 1
2001 2
2003 1
2004 1
2008 2
2009 2
2010 4
2011 2
2012 4
2013 6
2015 3
2016 3
2017 6
2018 1
2019 3
2020 4
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L. Guazzelli A, et al. Among authors: krstic demonacos m. Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Immunotherapy. 2017. PMID: 28231719 Free article. Review.
Immunotherapy advances for mesothelioma treatment.
Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L. Bakker E, et al. Among authors: krstic demonacos m. Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Expert Rev Anticancer Ther. 2017. PMID: 28724330 Free article. Review.
Targeting hypoxic response for cancer therapy.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Paolicchi E, et al. Among authors: krstic demonacos m. Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Oncotarget. 2016. PMID: 26859576 Free PMC article. Review.
Tremelimumab for the treatment of malignant mesothelioma.
Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: krstic demonacos m. Expert Opin Biol Ther. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515. Expert Opin Biol Ther. 2015. PMID: 26560442 Review.
The role of microenvironment and immunity in drug response in leukemia.
Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-Demonacos M. Bakker E, et al. Among authors: krstic demonacos m. Biochim Biophys Acta. 2016 Mar;1863(3):414-426. doi: 10.1016/j.bbamcr.2015.08.003. Epub 2015 Aug 6. Biochim Biophys Acta. 2016. PMID: 26255027 Free article. Review.
What can independent research for mesothelioma achieve to treat this orphan disease?
Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: krstic demonacos m. Expert Opin Investig Drugs. 2019 Aug;28(8):719-732. doi: 10.1080/13543784.2019.1638363. Epub 2019 Jul 1. Expert Opin Investig Drugs. 2019. PMID: 31262194 Review.
Is There Already a Need of Reckoning on Cancer Immunotherapy?
Correale P, Pentimalli F, Baglio G, Krstic-Demonacos M, Saladino RE, Giordano A, Mutti L. Correale P, et al. Among authors: krstic demonacos m. Front Pharmacol. 2021 Mar 26;12:638279. doi: 10.3389/fphar.2021.638279. eCollection 2021. Front Pharmacol. 2021. PMID: 33841155 Free PMC article. No abstract available.
Elimination of Off-Target Effect by Chemical Modification of 5'-End of siRNA.
Shiohama Y, Fujita R, Sonokawa M, Hisano M, Kotake Y, Krstic-Demonacos M, Demonacos C, Kashiwazaki G, Kitayama T, Fujii M. Shiohama Y, et al. Among authors: krstic demonacos m. Nucleic Acid Ther. 2022 Oct;32(5):438-447. doi: 10.1089/nat.2021.0068. Epub 2022 Apr 11. Nucleic Acid Ther. 2022. PMID: 35404139
52 results